Indaptus Therapeutics established an at-the-market (ATM) equity program to sell up to $100 million of common stock. H.C. Wainwright & Co. will manage the sales as the designated agent. This agreement, dated August 28, 2026, amends and replaces a previous ATM program from 2022.
The offering could significantly increase the company's total shares outstanding. At an illustrative price of $1.14 per share, Indaptus could issue over 87 million new shares. The company reported approximately 133 million shares outstanding as of August 26, 2026.
The company intends to use proceeds for working capital and general corporate purposes. The company’s auditor previously expressed substantial doubt regarding its ability to continue as a going concern.